A high-level overview of RedHill Biopharma Ltd. (RDHL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Redhill Biopharma Ltd是一家专注于胃肠道疾病的专业生物制药公司。该公司主要专注于推进其临床阶段治疗候选药物的开发管道。 该公司还在美国销售胃肠道相关产品 Talicia(奥美拉唑、阿莫西林和利福布丁)和 Aemcolo(利福霉素。 该公司目前的产品线由五种治疗候选药物组成,分别是Opaganib、RHB-107、RHB-102、RHB-204和RHB-...
Redhill Biopharma Ltd是一家专注于胃肠道疾病的专业生物制药公司。该公司主要专注于推进其临床阶段治疗候选药物的开发管道。 该公司还在美国销售胃肠道相关产品 Talicia(奥美拉唑、阿莫西林和利福布丁)和 Aemcolo(利福霉素。 该公司目前的产品线由五种治疗候选药物组成,分别是Opaganib、RHB-107、RHB-102、RHB-204和RHB-...
Get the latest Redhill Biopharma (REDIF) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Redhill Biopharma (RDHL) Is Weak On High Volume Today Trade-Ideas LLC identified Redhill Biopharma (RDHL) as a weak on high relative volume candidate RDHL Latest Stock Market News & Data Jun 5, 2014 4:02 PM EDT 3 Stocks Advancing The Drugs Industry TheStreet highlights 3 stocks that push...
RedHill is at the forefront of pandemic preparedness and medical countermeasures efforts, developing two novel, potentially broad-acting, host-directed, late-stage, oral, small molecule therapies, with intrinsic viral mutation-resistant properties, suitable for stockpiling and easy distribution and administ...
Redhill Biopharma(RDHL.US):2023年Q2财报实现营收179.6万美元,前值为1834.6万美元;每股收益为0.09美元,前值为-0.80美元。 Redhill Biopharma(RDHL.US)公司简介:Redhill Biopharma Ltd是一家专注于胃肠道疾病的专业生物制药公司。 该公司推广胃肠道药物,包括用于成人阿片类药物引起便秘的Movantik,用于治疗成人幽门螺杆菌...
RedHill is at the forefront of pandemic preparedness and medical countermeasures efforts, developing two novel, potentially broad-acting, host-directed, late-stage, oral, small molecule therapies, with intrinsic viral mutation-resistant properties, suitable for stockpiling and easy distribution and administ...
See the latest Redhill Biopharma Ltd ADR stock price (RDHL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
过去5年,Redhill Biopharma的股东应占净利润(持续经营业务)在Dezember 2023达到了 23.916百万的峰值。 Redhill Biopharma的股东应占净利润(持续经营业务)于Dezember 2021触及5年低点,是-97.744百万。 Redhill Biopharma的股东应占净利润(持续经营业务)于2019 (-42.304百万, +9.0%)、2020 (-76.173百万, +80.1%)和2021...